SITC Announces Co-Sponsored Workshop with U.S. Food and Drug Administration on Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials

Share Article

The Society for Immunotherapy of Cancer (SITC) is pleased to announce a new co-sponsored workshop with the U.S. Food and Drug Administration (FDA) on Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials. The free to attend workshop will take place on Nov. 8, 2018, from 2 – 6 p.m., at the Walter E. Washington Convention Center in Washington, D.C.

“SITC is proud to work with the FDA to help standardize design, conduct, data collection and analysis of an immune-modified response criteria for use in cancer immunotherapy clinical trials,” said SITC President Lisa H. Butterfield, PhD.

The Society for Immunotherapy of Cancer (SITC) is pleased to announce a new co-sponsored workshop with the U.S. Food and Drug Administration (FDA) on Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials. The free to attend workshop will take place on Nov. 8, 2018, from 2 – 6 p.m., at the Walter E. Washington Convention Center in Washington, D.C.

“SITC is proud to work with the FDA to help standardize design, conduct, data collection and analysis of an immune-modified response criteria for use in cancer immunotherapy clinical trials,” said SITC President Lisa H. Butterfield, PhD. “We look forward to evaluating current knowledge across all facets of regulatory and research programs towards the development of a rigorous tumor measurement-based endpoint that accounts for unique, immunological mechanisms of action as well as being suitable to support regulatory, payer, clinician and patient decision making.”

This FDA and SITC co-sponsored workshop will provide attendees with a forum for open discussion to share knowledge and provide education towards the development of a standardized immune-modified response criteria for use in cancer immunotherapy development programs intended to support marketing approval.

This program is organized by Michael B. Atkins, MD (Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center); Howard L. Kaufman, MD, FACS (Chief Medical Officer, Replimune Group Inc.); Samir N. Khleif, MD (Director, The Loop Immuno-Oncology Lab, Georgetown University); Ke Liu, MD, PhD (Chief of Oncology, FDA, CBER); and Marc Theoret, MD (Associate Director for Immunotherapeutics, FDA, Office of Hematology and Oncology Products).

This innovative workshop is free to attend and does not require registration to the 33rd Annual Meeting & Pre-Conference Programs taking place the same week at the Convention Center. Additional program information and registration instructions are available at the program website here.

About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Julia Schultz
@sitcancer
Follow >
Society for Immunotherapy of Cancer
Like >
Visit website